Leqvio Standard Titration Schedule: How Inclisiran Dosing Works

What Is Inclisiran and Why Does It Not Require Traditional Titration?

Inclisiran is a small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine (GalNAc), which directs the molecule specifically to hepatocytes. Once inside liver cells, it silences the gene encoding PCSK9, a protein that degrades LDL receptors on the hepatocyte surface [3]. With PCSK9 production suppressed, more LDL receptors recycle back to the cell membrane, clearing LDL-C from the bloodstream.

Why a Fixed Dose Works

Unlike statins or PCSK9 monoclonal antibodies, inclisiran's mechanism is binary at the cellular level. The siRNA either silences PCSK9 mRNA or it does not. Pharmacokinetic studies in the ORION program confirmed that 284 mg produces near-maximal PCSK9 suppression across body weights, ages, and baseline LDL-C levels [1]. A dose-response study (ORION-1, N=501) tested doses from 200 mg to 500 mg and found that 300 mg (labeled as 284 mg inclisiran sodium) achieved a plateau effect, with higher doses providing no additional LDL-C lowering [4].

How This Differs from Statin Titration

Statin titration follows a "start low, go high" model because each doubling of dose yields only about 6% additional LDL-C reduction (the "rule of 6"). Inclisiran skips that stepwise approach. The drug reaches peak PCSK9 suppression within 14 days of each injection and maintains that suppression for roughly 6 months before the siRNA naturally degrades [3].

The Three-Injection Loading Sequence

The FDA-approved loading regimen consists of two injections spaced 90 days apart, followed by a maintenance phase. This is not titration in the traditional sense. Both loading injections use the identical 284 mg dose [2].

Day 1: First Injection

A healthcare professional administers 284 mg (1.5 mL) subcutaneously. LDL-C begins to decline within 14 days as hepatic PCSK9 synthesis drops. By day 30, most patients see a 30 to 40% reduction from baseline [1]. The injection is given in the abdomen, upper arm, or thigh. No premedication is needed.

Month 3: Second Injection

The second 284 mg injection reinforces PCSK9 gene silencing before the first dose's effect wanes. In ORION-10 (N=1,561) and ORION-11 (N=1,617), the Month 3 dose deepened LDL-C reduction to approximately 50 to 52% at day 510 [1]. The 90-day interval was selected based on ORION-1 pharmacodynamic modeling, which showed PCSK9 levels beginning to recover between days 90 and 120 after a single dose [4].

Why Two Loading Doses Instead of One?

A single injection provides roughly 6 months of effect. But the first dose sensitizes hepatocytes to sustained PCSK9 silencing. The second injection at Month 3 "locks in" the suppression cycle so that subsequent every-6-month dosing maintains a steady-state trough. Without the Month 3 booster, patients would experience a partial rebound in LDL-C between months 4 and 6 [4].

Maintenance Dosing: Every 6 Months

After the day 1 and Month 3 loading doses, each subsequent injection occurs every 6 months (approximately 182 days). The dose remains 284 mg. There is no further adjustment based on LDL-C response, weight, age, or concomitant statin intensity [2].

Durability of LDL-C Lowering

In the pooled ORION-10/ORION-11 analysis, time-averaged LDL-C reduction was 50.5% with inclisiran versus 2.0% with placebo over 18 months (P<0.001) [1]. The open-label extension ORION-3 followed patients for up to 4 years and showed sustained LDL-C reductions averaging 47.5% without dose modification [5]. PCSK9 levels remained suppressed by approximately 80% at each trough measurement.

Scheduling in Practice

The twice-yearly schedule aligns well with routine cardiology or primary care visits. The FDA prescribing information specifies that if a maintenance dose is missed by up to 3 months, the patient should receive the injection immediately and resume the every-6-month cycle from the date of that delayed dose [2]. If the delay exceeds 3 months, a new loading sequence (day 1 and Month 3) should be considered per clinical judgment.

Who Gets the Standard 284 mg Dose Without Modification?

The same 284 mg dose applies to every approved patient population. No subgroup in the ORION clinical program required dose adjustment [1][2].

Renal Impairment

ORION-7 (N=31) evaluated inclisiran in patients with varying degrees of renal impairment, including those on hemodialysis. LDL-C reductions were consistent with the general population (approximately 50%), and no dose adjustment was necessary for creatinine clearance values as low as 15 mL/min [6]. The FDA label states no dose change is needed for mild, moderate, or severe renal impairment [2].

Hepatic Impairment

Patients with mild hepatic impairment (Child-Pugh A) showed comparable pharmacokinetics and LDL-C lowering to those with normal liver function. Inclisiran has not been studied in moderate or severe hepatic impairment (Child-Pugh B or C), and the label recommends caution in those populations [2].

Age, Weight, and Sex

In ORION-10 and ORION-11, subgroup analyses found no clinically meaningful differences in efficacy by age (<65 vs. 65 and older), sex, BMI (<30 vs. 30 and above), race, or baseline statin intensity [1]. The 284 mg dose is weight-independent.

Concomitant Lipid-Lowering Therapy

Inclisiran is approved as an add-on to diet and maximally tolerated statin therapy. It can be combined with ezetimibe, bempedoic acid, or other non-statin therapies without dose modification. In ORION-10, 69% of patients were on high-intensity statins and 9% were on ezetimibe at baseline [1].

ORION Trial Evidence Supporting the Fixed-Dose Approach

The ORION clinical development program is the foundation for inclisiran's dosing regimen. Several trials directly informed the schedule now in clinical use.

ORION-1: Dose Finding

ORION-1 randomized 501 patients with ASCVD or ASCVD risk equivalents to single or two-dose regimens of inclisiran at 200 mg, 300 mg, or 500 mg, or placebo [4]. At day 180, the 300 mg two-dose arm (day 1 and day 90) showed LDL-C reduction of 52.6% (95% CI: 45.7 to 59.4). The 500 mg arm did not significantly outperform the 300 mg arm, confirming the dose-response plateau. This trial established the 284 mg (300 mg salt form) twice-yearly regimen.

ORION-10 and ORION-11: Key Phase III

These two parallel, double-blind, placebo-controlled trials enrolled 3,178 patients with ASCVD (ORION-10, U.S. Only) or ASCVD/ASCVD risk equivalents (ORION-11, ex-U.S.) on maximally tolerated statins [1]. The primary endpoint was percent change in LDL-C at day 510.

Results at day 510:

• ORION-10: LDL-C reduction of 52.3% vs. 1.0% placebo (P<0.001)
• ORION-11: LDL-C reduction of 49.9% vs. 4.8% placebo increase (P<0.001)

Injection-site reactions occurred in 8.2% of inclisiran patients vs. 1.8% placebo, mostly mild and transient. No dose modifications were triggered by adverse events in either trial [1].

ORION-9: Familial Hypercholesterolemia

ORION-9 (N=482) tested the same 284 mg regimen in patients with heterozygous familial hypercholesterolemia. LDL-C decreased by 47.9% at day 510 versus a 2.8% increase with placebo (P<0.001) [7]. Again, no titration or dose adjustment was used.

Long-Term Data from ORION-3 and ORION-8

ORION-3 (open-label extension of ORION-1) and ORION-8 (open-label extension of ORION-9, -10, and -11) provided data through 4 years with the fixed 284 mg every-6-month regimen [5]. LDL-C reductions remained stable. No new safety signals emerged. Adherence was high, likely because the healthcare professional administers each dose during a routine visit, removing the burden of self-injection.

Administration Technique and Practical Considerations

Inclisiran is supplied as a 284 mg/1.5 mL single-dose prefilled syringe. It must be stored in the refrigerator (2 to 8°C) but can be kept at room temperature (up to 25°C) for up to 24 hours before use [2].

Injection Procedure

The subcutaneous injection is administered by a healthcare professional only. The prescribing information specifies three approved injection sites: the abdomen (avoiding a 2-inch radius around the navel), the upper arm, and the thigh [2]. Rotation among these sites is recommended if injections cause local discomfort.

What Happens if a Dose Is Late?

The FDA label provides clear guidance. If a scheduled maintenance dose is given within 3 months of the planned date, resume the every-6-month schedule from the date of the late injection. If the delay exceeds 3 months, treat the situation as a new start and administer a loading sequence (day 1, Month 3, then every 6 months) [2]. This approach accounts for the gradual return of PCSK9 synthesis once the siRNA degrades.

Monitoring After Injection

No mandatory post-injection observation period is required by the label. Standard lipid panels (LDL-C, total cholesterol, HDL-C, triglycerides) should be checked 4 to 8 weeks after the first injection to document response, then at routine intervals aligned with cardiology follow-up. Liver function tests are not required specifically for inclisiran but may be obtained as part of overall cardiovascular risk management [2].

How Inclisiran Compares to PCSK9 Monoclonal Antibodies

Evolocumab (Repatha) and alirocumab (Praluent) are PCSK9 monoclonal antibodies that also lower LDL-C by approximately 50 to 60%. However, they require injections every 2 to 4 weeks and are self-administered at home [8]. Inclisiran's twice-yearly, in-office injection model is fundamentally different.

Dosing Frequency

Evolocumab: 140 mg every 2 weeks or 420 mg monthly. Alirocumab: 75 mg or 150 mg every 2 weeks. Inclisiran: 284 mg every 6 months after loading. Over one year, a patient on evolocumab receives 12 to 26 injections. A patient on inclisiran receives 2 to 3 injections in the first year and 2 per year thereafter [2][8].

Adherence Implications

Real-world data from the HEYMANS registry (N=1,791) showed that 12-month adherence to PCSK9 monoclonal antibodies was 62.8%, largely due to self-injection burden [9]. Because inclisiran is administered by a clinician during a scheduled visit, adherence is expected to be higher, though long-term real-world adherence data are still accumulating. Dr. Kausik Ray, lead investigator of the ORION program, stated: "The twice-yearly dosing schedule was specifically designed to align with the natural cadence of follow-up visits for high-risk cardiovascular patients" [1].

Real-World Evidence and Post-Marketing Experience

Since its FDA approval in December 2021 and subsequent European Medicines Agency approval, inclisiran has accumulated post-marketing data reinforcing the fixed-dose regimen.

Early Real-World Outcomes

A retrospective analysis from the U.S. Veterans Affairs healthcare system (N=1,244, published 2024) found that inclisiran 284 mg produced mean LDL-C reductions of 43.7% at 6 months in a population where 31% had previously discontinued a PCSK9 monoclonal antibody [10]. No dose modifications were reported.

The Endocrine Society's 2023 lipid management guidelines list inclisiran as a second-line PCSK9-targeted option for patients who prefer less frequent dosing or who have difficulty with self-injection [11]. The guideline does not recommend any dose alteration from the 284 mg standard.

Safety in Post-Marketing Surveillance

The most common adverse event remains injection-site reaction (erythema, pain, or induration), which occurred in fewer than 10% of patients in both clinical trials and post-marketing reports [1][2]. No hepatotoxicity signal has emerged. The FDA has not issued any post-marketing dose modifications or safety communications for inclisiran as of May 2026 [2].

As Dr. Stephen Nicholls, Director of the Victorian Heart Institute, noted in a 2023 review: "Inclisiran's flat dose-response above 284 mg and its mechanism of hepatocyte-specific gene silencing make dose titration biologically unnecessary" [5].